Appendix 4D and Interim Financial Report
Filed with ASX · · 25 pages · English
Summary by 6ix AI
The report highlights a substantial increase in the loss from ordinary activities after tax compared to the previous year, attributed mainly to increased research and development costs. The company did not declare any dividends during this period, maintaining a focus on funding its ongoing operations through various means.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Recce Enters Second U.S. Department of Defense R&D Agreement
- Quarterly Activities/Appendix 4C Cash Flow Report
- AUD $5.3m R&D Rebate Received
- RCE Awarded Advanced Overseas Finding up to A$85m
- Hong Kong Patent Granted for RECCE Anti-Infectives
Later from Recce Pharmaceuticals
- RCE Investor Webinar Presentation Deck
- Brazil Patent Granted for RECCE Anti-Infectives
- Recce Signs Middle East Licensing Term Sheet
- Addendum to Recce Signs Middle East Licensing Term Sheet
- HREC Approval Accelerates Global Phase 3 DFI Strategy
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals